mastodon 4.7.2Cheif Science and Strategy Officer, openRxiv. bioRxiv and medRxiv Co-Founder.
New version of our preprint on bioRxiv about bioRxiv. Now that’s what I call a revision – 6 years after the first version!
It has new data about our progress and highlights from a massive user survey.
bioRxiv continues to grow – a brief spike and lag in the pandemic (details of which are included) but a steady increase in submissions since then. % revisions, license choice, etc. all fairly constant. 0.1% withdrawal rate is comparable to journal retraction rates.
Preprints of pandemic potential - new historical piece from me on the history of bioRxiv/medRxiv, their role in the pandemic, and the way forward.
Their success was far from a given and is a tribute to the scientific community. It felt important to tell the story and recognize the contributions of so many: CSHL, our amazing internal team, the scientists who inspired us, & and of course CZI and our other funders for their vision 1/n
"as [bioRxiv and medRxiv ] become essential infrastructure, it makes sense to be supported by a diversity of stakeholders..several institutions offered financial support, including Stanford, MIT, Caltech, CNRS, Fred Hutch, Imperial, UW, & VU Amsterdam"
🙏 🙏🙏 to all who have helped. The vision of bioRxiv/medRxiv has always been a non-profit, community effort and that includes funding. So if your institution would like to help too, please do get in touch!
https://investinopen.org/blog/infrastructure-spotlight-biorxiv-and-medrxiv/
Data all the way down: How uncovering the data underlying research findings impacts every aspect of scholarly communication - webinar today at 12 pm ET
https://events.humanitix.com/love-data-week-panel-discussion-data-all-the-way-down
Heading out to #cellbio2025. bioRxiv/medRxiv/openRxiv have booth 1134. swing by or ping me here if you want to chat preprints and all things sci comm
